An interventional study of Enhanced First Trimester GDM Screening and Routine Gestational Diabetes Screening in Gestational Diabetes Mellitus in Pregnancy and Pregnancy, High Risk, sponsored by University of Massachusetts, Worcester. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by University of Massachusetts, Worcester · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 251 studies in Diabetes, Gestational with a site in United States — 52 open to participants now, 65 under way, 2 of them phase 3. Diabetes, Gestational · United States.
Among the 251 studies in Diabetes, Gestational with a site in United States, this one is the 97th largest by planned enrollment of the 194 interventional ones that give a count, is one of 25 that started in 2025, is one of 154 with no phase, reaches primary completion later than 27 of the 64 other live ones, and was the 176th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →52 of the 251 studies in Diabetes, Gestational with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 20–40 · Women only
Medical College of Wisconsin · Sites in United States
Ages 18+ · Women only
Texas A&M University · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
University of Hawaii · Sites in United States
Ages 18+ · Women only
University of California, Davis · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
251 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 11 · Phase 3 9 · Phase 4 11
First in 2000; this study’s year is marked. 25 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.
Median enrollment 80 across the 194 interventional studies, 72 across the 57 observational. Of the 154 that completed or were terminated, 35 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 251 have an industry lead sponsor. The 10 most frequent:
University of Massachusetts, Worcester is the lead sponsor of 291 studies on the registry; 50 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
University of Massachusetts, Worcester has 3 studies filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
22 of the studies in Diabetes, Gestational with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07356180University of Maryland, BaltimorePhysical Acvitiy in Pregnancy | 2026-12 |
| NCT05909046Ohio State UniversityA Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE | 2026-12 |
| NCT05388643University of Massachusetts, WorcesterEarly Detection of Gestational Diabetes Mellitus in Pregnancy | 2026-12-01 |
| NCT07176793University of California, DavisPregnancy and Postpartum Breastfeeding Support for Patients With Gestational Diabetes | 2026-12-30 |
| NCT05124808Indiana UniversityIntensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 251 studies in Diabetes, Gestational with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to develop an implementation protocol and test the feasibility and acceptability of a first trimester screening protocol for the early detection of gestational diabetes mellitus (GDM).
Gestational diabetes mellitus (GDM) is an important contributor to both maternal and neonatal morbidity and mortality in pregnancy. GDM has lifelong complications including an increased risk of developing type 2 diabetes mellitus and cardiovascular disease for women, and their offspring are at higher risk of being obese and also having diabetes in childhood and adolescence. Approximately 1 in 8 pregnancies is impacted by gestational diabetes mellitus worldwide. First trimester GDM screening is varied due to conflicting national guidelines, and the best strategy is unknown. The goal of the proposed research is to develop an implementation protocol and test the feasibility and acceptability of a first trimester screening protocol for the early detection of GDM. The investigators will utilize a pilot randomized controlled trial to recruit 80 high-risk pregnant women in the first trimester, of whom half will receive protocolized early GDM screening with serum biomarkers before 12 weeks and the remaining half will receive the current standard of care with screening between 24 and 28 weeks of gestation with possible early screening based on provider discretion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.
Diagnostic Test: Enhanced First Trimester GDM Screening
Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.
Diagnostic Test: Routine Gestational Diabetes Screening
Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.
Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.
Also known as: Third Trimester Screening
Gestational Diabetes Mellitus
Confirmed diagnosis of GDM based on 3 hour 100 gram glucose tolerance test
Time frame: In pregnancy (24-28 weeks gestation)
Mode of Delivery
Mode of delivery (Vaginal versus Cesarean delivery)
Time frame: At Birth
Neonatal Birthweight
Neonatal Birthweight
Time frame: At Birth
Number of Participants with Shoulder Dystocia
Number of Participants with Shoulder Dystocia
Time frame: At Birth
Number of participants with brachial plexus injury
Number of participants with brachial plexus injury
Time frame: At Birth
APGAR Score
APGAR Score (range 0 to 10, with 10 being the best)
Time frame: At Birth
Neonatal Intensive Care Unit Admission
Admission to Level 2 or greater neonatal ICU and length of stay
Time frame: At delivery and within first 2 days of life
Gestational Age at Delivery
Gestational Age at Delivery
Time frame: At Birth
Patient Satisfaction with Diabetes Screening Method
This will be assessed by the Patient Satisfaction Survey questionnaire, which is scored out of 30, with 30 being the highest score)
Time frame: Postpartum day 1 after birth
Plan to share: No
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 17 months is below that.
Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Massachusetts, Worcester →